Exénatide (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Exénatide" in French language version.

refsWebsite

Global rank French rank

2jamanetwork.com

2,650^th place

689^th place

2nih.gov

4^th place

12^th place

2doi.org

2^nd place

3^rd place

2wikipedia.org

low place

2fda.gov

447^th place

1,409^th place

2thelancet.com

2,393^rd place

506^th place

2diabetesjournals.org

low place

7,774^th place

1qmul.ac.uk

1,735^th place

168^th place

1eje-online.org

low place

1europa.eu

68^th place

67^th place

1liebertpub.com

low place

4,955^th place

1endojournals.org

low place

3,196^th place

1nejm.org

2,374^th place

298^th place

1sciencedirect.com

149^th place

80^th place

diabetesjournals.org

diabetes.diabetesjournals.org

(en) (en) A.E Butler, M. Campbell-Thompson, T. Gurlo, D.W. Dawson, M. Atkinson, P.C. Butler, « Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors », Diabetes, vol. 62, n^o 7,‎ 2013, p. 2595-2604 (PMID 23524641, PMCID PMC3712065, DOI 10.2337/db12-1686, lire en ligne [html], consulté le 28 mars 2013) modifier

care.diabetesjournals.org

Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study, Diabetes Care, 2012;35:252-258

doi.org

dx.doi.org

(en) (en) S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, « Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study », JAMA internal medicine, vol. 173, n^o 7,‎ 2013, p. 1-6 (PMID 23440284, DOI 10.1001/jamainternmed.2013.2720, lire en ligne [html], consulté le 28 mars 2013) modifier
(en) (en) A.E Butler, M. Campbell-Thompson, T. Gurlo, D.W. Dawson, M. Atkinson, P.C. Butler, « Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors », Diabetes, vol. 62, n^o 7,‎ 2013, p. 2595-2604 (PMID 23524641, PMCID PMC3712065, DOI 10.2337/db12-1686, lire en ligne [html], consulté le 28 mars 2013) modifier

eje-online.org

Van Gaal LF, Gutkin SW, Nauck MA, Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists or insulin for patients with inadequate glycemic control?, Eur. J. Endocrinol., 2008;158:773-784

endojournals.org

jcem.endojournals.org

Blevins T, Pullman J, Malloy J et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes, J Clin Endocrinol Metab, 2011;96:1301-1310

europa.eu

ema.europa.eu

[PDF](en) Communiqué de presse EMA 26 mars 2013

fda.gov

jamanetwork.com

archinte.jamanetwork.com

Singh S, Chang H-Y, Richard TM, Weiner JP, Clark JM, Segal JB, Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study, JAMA Intern Med, 2013
(en) (en) S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, « Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study », JAMA internal medicine, vol. 173, n^o 7,‎ 2013, p. 1-6 (PMID 23440284, DOI 10.1001/jamainternmed.2013.2720, lire en ligne [html], consulté le 28 mars 2013) modifier

liebertpub.com

online.liebertpub.com

DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P, Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes, Diabetes Technol Ther, 2011;13:1145-1154

nejm.org

Holman RR, Bethel MA, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 2017;377:1228-1239

nih.gov

ncbi.nlm.nih.gov

(en) (en) S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, « Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study », JAMA internal medicine, vol. 173, n^o 7,‎ 2013, p. 1-6 (PMID 23440284, DOI 10.1001/jamainternmed.2013.2720, lire en ligne [html], consulté le 28 mars 2013) modifier
(en) (en) A.E Butler, M. Campbell-Thompson, T. Gurlo, D.W. Dawson, M. Atkinson, P.C. Butler, « Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors », Diabetes, vol. 62, n^o 7,‎ 2013, p. 2595-2604 (PMID 23524641, PMCID PMC3712065, DOI 10.2337/db12-1686, lire en ligne [html], consulté le 28 mars 2013) modifier

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sciencedirect.com

Athauda D, Maclagan K, Skene SS et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial, Lancet, 2017;390:1664-1675

thelancet.com

Drucker DJ, Buse JB, Taylor K, et als for the DURATION-1 Study Group, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet 2008,372:1240-1250
Buse JB, Nauck M, Forst T, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 2013;381:117-124

wikipedia.org

fr.wikipedia.org

(en) (en) S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, « Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study », JAMA internal medicine, vol. 173, n^o 7,‎ 2013, p. 1-6 (PMID 23440284, DOI 10.1001/jamainternmed.2013.2720, lire en ligne [html], consulté le 28 mars 2013) modifier
(en) (en) A.E Butler, M. Campbell-Thompson, T. Gurlo, D.W. Dawson, M. Atkinson, P.C. Butler, « Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors », Diabetes, vol. 62, n^o 7,‎ 2013, p. 2595-2604 (PMID 23524641, PMCID PMC3712065, DOI 10.2337/db12-1686, lire en ligne [html], consulté le 28 mars 2013) modifier